Biosimilars of adalimumab: the upcoming challenge in IBD-Reference-Cited by-同舟云学术

Biosimilars of adalimumab: the upcoming challenge in IBD

Published:2019-01-08 Issue:10 Volume:19 Page:1023-1030
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Fiorino Gionata¹²,Gilardi Daniela¹,Correale Carmen¹,Furfaro Federica¹,Roda Giulia¹,Loy Laura¹,Argollo Marjorie¹^ORCID,Allocca Mariangela¹²,Peyrin-Biroulet Laurent³,Danese Silvio¹²^ORCID

Affiliation:

1. IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Institute, Milan, Italy

2. Department of Biomedical Sciences, Humanitas University, Milan, Italy

3. Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France

Funder

funded

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2019.1564033

Reference55 articles.

1. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

2. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

3. Research and markets global monoclonal antibodies market - by type, application, region - market size, demand forecasts, company profiles, industry trends and updates (2017–2023). [cited Aug 17]. Available from: https://www.researchandmarkets.com/research/mmpjv5/global_131_33?w=4

4. Technavio global anti-inflammatory therapeutics market 2017-2021. [cited Aug 17]. Available from: https://www.technavio.com/report/global-anti-inflammatory-therapeutics-market?utm_source=t2&utm_medium=bw&utm_campaign=businesswire

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Course of Bio Naive Ulcerative Colitis Patients Five Years After Initiation of Adalimumab in a Nationwide Cohort;Crohn's & Colitis 360;2024-07-01

2. α-mangostin derivatives ameliorated mouse DSS-induced chronic colitis via regulating Th17/Treg balance;Molecular Immunology;2024-02

3. Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID;Therapeutic Advances in Gastroenterology;2024-01

4. The role of inflammation in autoimmune disease: a therapeutic target;Frontiers in Immunology;2023-10-04

5. Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia;Expert Opinion on Biological Therapy;2023-04-19